In a time of increasing cost pressures, limited resource capacity, and heightened demand for new treatments, Health Technology Assessments (HTAs) play a vital role in evaluating whether new interventions will provide sufficient patient benefits to justify the cost to the health service.
Learn more about how burden of illness (BoI) studies alongside PRO data in HTA submissions can help decision-makers to make more informed decisions.
Article first published in Pharmaphorum October 2022.
